Compare
HCW Biologics Inc. vs Lunai Bioworks Inc. vs Avalo Therapeutics, Inc. vs Connect Biopharma Holdings Ltd
| Latest fiscal year | HCW Biologics Inc. HCWB | Lunai Bioworks Inc. LNAI | Avalo Therapeutics, Inc. AVTX | Connect Biopharma Holdings Ltd CNTB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $54.2K | $52.0K | $59.0K | $64.0K |
| Revenue growth (YoY) | -97.9% | n/a | -86.6% | -99.8% |
| Gross margin | 20.0% | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$7.96M | -$3.56M | -$78.26M | -$55.48M |
| EPS (Diluted) | -$10.63 | -$1.06 | -$5.84 | -$1.00 |
| Operating cash flow | -$13.39M | -$5.29M | -$51.46M | -$51.21M |
| Free cash flow | -$13.39M | -$5.29M | n/a | -$51.64M |
| Cash & equivalents | $1.95M | $1.71M | $15.86M | $38.34M |
| Total assets | $24.52M | $9.94M | $116.46M | $56.08M |
| Total liabilities | $21.76M | $18.97M | $33.41M | $14.10M |
| Shareholders' equity | $2.76M | -$9.02M | $83.05M | $41.98M |
| Return on year-end equity | -287.9% | n/a | -94.2% | -132.2% |
| Shares outstanding | n/a | 4.62M | 18.51M | 56.44M |
Revenue, most recent five fiscal years
| Fiscal year | HCW Biologics Inc. | Lunai Bioworks Inc. | Avalo Therapeutics, Inc. | Connect Biopharma Holdings Ltd |
|---|---|---|---|---|
| Latest | $54.2K Ended 2025-12-31 | $52.0K Ended 2026-06-30 | $59.0K Ended 2025-12-31 | $64.0K Ended 2025-12-31 |
| 1 year earlier | $2.57M Ended 2024-12-31 | n/a | $441.0K Ended 2024-12-31 | $26.03M Ended 2024-12-31 |
| 2 years earlier | $2.84M Ended 2023-12-31 | n/a | $1.92M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $6.72M Ended 2022-12-31 | n/a | $18.05M Ended 2022-12-31 | n/a |
| 4 years earlier | $0 Ended 2021-12-31 | n/a | $5.40M Ended 2021-12-31 | n/a |